New GE-Backed Heart Disease Study May Advance Detection To Never Before Seen Levels
GE Healthcare and Lantheus Holdings Inc (NASDAQ:LNTH) announced that the recent Phase 3 trial of a radiotracer, [18F]flurpiridaz, has met its co-primary…
FDA Clears Akouos’ Gene Therapy Trial For Genetic Form Of Hearing Loss
The FDA has signed off Akouos Inc’s (NASDAQ:AKUS) Investigational New Drug application to initiate a Phase 1/2 trial of AK-OTOF, gene…
SEC Charges VMWare With Fraud, But Settled For Just $8M In Penalty
The Securities and Exchange Commission said it had charged the cloud computing giant VMware Inc (NYSE: VMW) for “misleading investors about its order backlog management practices.
FDA Schedules AdComm Review For First Over The Counter Birth Control Pill
The FDA has set a date to review what could become the first over-the-counter birth control pill approved in the…
At R&D Day, Alpine Immune Highlights Updates On Autoimmune, Immuno-Oncology Programs
Alpine Immune Sciences Inc (NASDAQ:ALPN) announced clinical updates from ALPN-303 and davoceticept programs. Key highlights from the announcement include: ALPN-303 Well…
KKR’s A$14.5B Takeover Bid Of Australia’s Ramsay Health Care Hits A Snag
Talks regarding KKR & Co (NYSE:KKR)-led consortium buying Australian hospital operator Ramsay Health Care Ltd (OTC:RMSYF) (OTC:RMYHY) have hit a snag. The consortium…
Analyst Outlines Doubts On This NASH-Focused Stock, Builds Neutral Case
HC Wainwright initiated Terns Pharmaceutical Inc (NASDAQ:TERN) with a Neutral rating and a price target of $6.00. The biopharmaceutical company has a…
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
HC Wainwright initiated coverage on Rain Therapeutics Inc (NASDAQ:RAIN), with a price target of $10 with a Buy rating. With an upside…
Deciphera Earns Price Target Bump With Encouraging ESMO Presentation
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) announced positive initial data from the single agent dose escalation portion of the Phase 1 study of…